86974680NSC1001
Phase I · Status: active · NSCLC
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer DE ↗
Klinische Studien: Lunge und Bronchien
Klinische Studien zu onkologischen Erkrankungen im Bereich Lunge und Bronchien am CCCC Berlin – unter anderem Adenokarzinom, Neuroendokrin (NET and NEC) und NSCLC.
ART 01
Status: active · Karzinom
Entwicklung einer digitalen Anwendung für die automatisierte adaptive Präzisionsstrahlentherapie des Lungenkarzinoms mit Patientenfeedback DE ↗
Artemia
Phase III · Status: active · NSCLC
A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune… DE ↗
BAY 22615 SOHO 02
Phase III · Status: active · NSCLC
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with… DE ↗
BNT327-03
Phase III · Status: active · Karzinom
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in… DE ↗
C5751003
Phase III · Status: active · NSCLC
An Open-Label, Randomized, Controlled Phase 3 Study Of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy As First-Line Treatment In Participants With Pd-L1 High (=50% Of Tumor… DE ↗
CA224-1093
Phase III · Status: active · NSCLC
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage… DE ↗
EP0031-101
Phase I/II · Status: active · Karzinom
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies DE ↗
GS-US-600-6165
Phase III · Status: active · Neuroendokrin (NET and NEC)
A Global, Multicenter, Randomized, Open-label, Phase 3 study of Sacituzumab Govitecan versus Standard of Care (SoC) in Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) DE ↗
HULU Projekt
Status: active · Karzinom, NSCLC
Pathogen-induzierte Aktivierung humaner Lungen, Analyse von Lungengewebeproben;Studie mit wissenschaftlicher feingeweblicher und biochemischer Untersuchung DE ↗
J3M-MC-JZQB
Phase III · Status: active · NSCLC
A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in… DE ↗
Krascendo 2
Phase III · Status: active · NSCLC
A phase III, randomized, open-label study evaluating the efficacy and safety of DIVARASIB and pembrolizumab versus pembrolizumab and pemetrexed and CARBOPLATIN or CISPLATIN in patients with previously untreated, KRAS… DE ↗
Lilly JOXA
Phase I · Status: active · Adenokarzinom
Lilly JOXA DE ↗
M18-868
Phase III · Status: active · NSCLC
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic… DE ↗
MK-2870-007
Phase III · Status: active · NSCLC
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With… DE ↗
MK-2870-019
Phase III · Status: active · NSCLC
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With… DE ↗
MK-2870-023
Phase III · Status: active · NSCLC
Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous… DE ↗
MK3475-U01H
Phase II · Status: active · NSCLC
KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants with Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) DE ↗
MK3475-U01I
Phase II · Status: active · NSCLC
KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) DE ↗
RMC-LUNG-101
Phase I/II · Status: active · NSCLC
Eine Plattform-Studie zur Therapie mit Kombinationen aus RAS(ON)-Inhibitoren und anderen antineoplastischen Substanzen in Patienten mit RAS-mutierten NSCLC DE ↗
Scorpion STX 721-101
Phase I/II · Status: active · NSCLC
First-In-Human Study of STX-721 In Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations DE ↗
SGNPDL1V-001
Phase I · Status: active · Karzinom
A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors DE ↗
Ihre Situation ist nicht dabei?
Auch wenn hier keine passende Studie gelistet ist, kann eine molekulare Diagnostik neue Behandlungsoptionen aufzeigen. Sprechen Sie unsere Cancer Hotline an.
Cancer Hotline kontaktieren ↗Das CCCC bietet neben Studien weitere Unterstützung, etwa Psychoonkologie oder Ernährungsberatung. Weitere Angebote des CCCC ↗